Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06809595 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
A Phase 3 study of Generalized Anxiety Disorder, sponsored by Definium Therapeutics US.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06809595: Recruiting Phase 3 study of Generalized Anxiety Disorder, sponsored by Definium Therapeutics US.
NCT06809595 is a Phase 3 study of Generalized Anxiety Disorder that is actively recruiting participants, run by Definium Therapeutics US. The registered enrollment target is 250 participants, above the 210-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06809595, a Phase 3 study of Generalized Anxiety Disorder, is actively recruiting participants, sponsored by Definium Therapeutics US.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Primary Outcome
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MM120 (LSD D-Tartrate)
Study Locations (20)
Other
- A-shine s.r.o. - Pilsen
- Institut Neuropsychiatricke Pece (INEP) - Prague
- Psyon s.r.o. - Prague
- Cabinet Dr.Desbonnet : Résidence Saint Michel - Douai
- Hôpital Conception, CIC Centre, bat néphrologie 3eme étage - Marseille
California
- Psychedelic Science Institute - Los Angeles
- West Los Angeles VA Medical Center - Los Angeles
- Cenexel-CNS - Torrance
Florida
- Bradenton Research Center, Inc. - Bradenton
- Clinical Neuroscience Solutions, Inc - Orlando
Ohio
- University of Cincinnati Psychiatry- Anxiety Disorders Research Program - Cincinnati
- Neuro-Behavioral Clinical Research, Inc. - North Canton
Arkansas
- Preferred Research Partners, Inc. - Little Rock
Georgia
- Atlanta Center for Medical Research - Atlanta
Maryland
- Sheppard Pratt Health System - Towson
Massachusetts
- Adams Clinical Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-01-29 |
| Est. Completion | 2027-05 |
| Phase | Phase 3 |
What NCT06809595 shows while recruiting
NCT06809595 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 210-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (19% higher).
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06809595 names 20 study sites across 12 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06809595 about?
NCT06809595 is a clinical study titled "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)". A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
What is the current status of trial NCT06809595?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2025-01-29. Estimated completion is 2027-05.
What conditions does trial NCT06809595 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT06809595?
The interventions under investigation include: Placebo (OTHER), MM120 (LSD D-Tartrate) (DRUG).
Who is sponsoring clinical trial NCT06809595?
This trial is sponsored by Definium Therapeutics US, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06809595 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06809595's enrollment target sits among peer trials
250 15th of 48 higher than 33 of 48 other Generalized Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
RECRUITING · Phase 3
-
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Long Term Chamomile Therapy for Anxiety
COMPLETED · Phase 3
-
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI